Literature DB >> 31296295

Evaluation of 30-Day Hospital Readmission and Mortality Rates Using Regression-Discontinuity Framework.

Rohan Khera1, Yongfei Wang2, Khurram Nasir2, Zhenqiu Lin3, Harlan M Krumholz4.   

Abstract

BACKGROUND: The Hospital Readmissions Reduction Program (HRRP) has been associated with reduced 30-day readmissions for acute myocardial infarction (AMI) and heart failure (HF).
OBJECTIVES: The purpose of this study was to test whether this 30-day readmission reduction is a manifestation of practices that defer or avoid hospitalizations beyond the 30-day period.
METHODS: At all U.S. hospitals under HRRP, the authors calculated daily readmission rates for elderly Medicare fee-for-service beneficiaries through day-60 post-discharge following a hospitalization for AMI and HF-the 2 target cardiovascular conditions-as well as pneumonia in July 2008 to June 2016. The authors applied a robust bias-corrected nonparametric regression approach to evaluate for discontinuities in rates around day 30.
RESULTS: The authors identified 3,256 eligible hospitals, with median readmission rates in the days 1 to 30 and 31 to 60 post-discharge of 19.6% (interquartile range [IQR]: 16.7% to 22.9%) and 7.8% (IQR: 6.5% to 9.4%) for AMI, 23.0% (IQR: 20.6% to 25.3%) and 11.4% (IQR: 10.2% to 12.6%) for HF, and 17.5% (IQR: 15.4% to 19.8%) and 8.3% (IQR: 7.3% to 9.3%) for pneumonia, respectively. Daily readmission rates decreased across most of the 60 post-discharge days, with no discontinuities in the local polynomial regression for readmission at the 30-day mark, with a >95% power to detect 0.1% difference for each outcome across post-discharge day 30. Similarly, there was no discontinuity in mortality at 30 days post-discharge, or for either outcome at hospitals that incurred readmission penalties.
CONCLUSIONS: There was no evidence that clinicians adopted strategies that specifically deferred admissions or affected mortality in the 30-day period after discharge. The findings are consistent with the institution of strategies that generally affected readmission risk after discharge.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hospital Readmissions Reduction Program; health policy; outcomes research; quality of care

Mesh:

Year:  2019        PMID: 31296295      PMCID: PMC8669780          DOI: 10.1016/j.jacc.2019.04.060

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  The Hospital Readmissions Reduction Program: Evidence for Harm.

Authors:  Ankur Gupta; Gregg C Fonarow
Journal:  JACC Heart Fail       Date:  2018-06-06       Impact factor: 12.035

2.  Readmissions, Observation, and the Hospital Readmissions Reduction Program.

Authors:  Rachael B Zuckerman; Steven H Sheingold; E John Orav; Joel Ruhter; Arnold M Epstein
Journal:  N Engl J Med       Date:  2016-02-24       Impact factor: 91.245

3.  Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure.

Authors:  Ankur Gupta; Larry A Allen; Deepak L Bhatt; Margueritte Cox; Adam D DeVore; Paul A Heidenreich; Adrian F Hernandez; Eric D Peterson; Roland A Matsouaka; Clyde W Yancy; Gregg C Fonarow
Journal:  JAMA Cardiol       Date:  2018-01-01       Impact factor: 14.676

4.  The heart failure readmission quagmire: taking a deep dive to find solutions.

Authors:  Rohan Khera; Ambarish Pandey
Journal:  Eur J Heart Fail       Date:  2017-11-30       Impact factor: 15.534

5.  Hospital readmissions reduction program.

Authors:  Colleen K McIlvennan; Zubin J Eapen; Larry A Allen
Journal:  Circulation       Date:  2015-05-19       Impact factor: 29.690

6.  Hospital strategies associated with 30-day readmission rates for patients with heart failure.

Authors:  Elizabeth H Bradley; Leslie Curry; Leora I Horwitz; Heather Sipsma; Yongfei Wang; Mary Norine Walsh; Don Goldmann; Neal White; Ileana L Piña; Harlan M Krumholz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-07

7.  Publicly Reported Readmission Measures and the Hospital Readmissions Reduction Program: A False Equivalence?

Authors:  Rohan Khera; Leora I Horwitz; Zhenqiu Lin; Harlan M Krumholz
Journal:  Ann Intern Med       Date:  2018-03-27       Impact factor: 25.391

8.  Contemporary data about hospital strategies to reduce unplanned readmissions: what has changed?

Authors:  Elizabeth H Bradley; Heather Sipsma; Leora I Horwitz; Leslie Curry; Harlan M Krumholz
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

9.  Post-hospital syndrome--an acquired, transient condition of generalized risk.

Authors:  Harlan M Krumholz
Journal:  N Engl J Med       Date:  2013-01-10       Impact factor: 91.245

10.  Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study.

Authors:  Kumar Dharmarajan; Angela F Hsieh; Vivek T Kulkarni; Zhenqiu Lin; Joseph S Ross; Leora I Horwitz; Nancy Kim; Lisa G Suter; Haiqun Lin; Sharon-Lise T Normand; Harlan M Krumholz
Journal:  BMJ       Date:  2015-02-05
View more
  9 in total

Review 1.  Economic Issues in Heart Failure in the United States.

Authors:  Paul A Heidenreich; Gregg C Fonarow; Yekaterina Opsha; Alexander T Sandhu; Nancy K Sweitzer; Haider J Warraich
Journal:  J Card Fail       Date:  2022-01-24       Impact factor: 6.592

2.  Impact of Pharmacist-Driven Transitions of Care Interventions on Post-hospital Outcomes Among Patients With Coronary Artery Disease: A Systematic Review.

Authors:  Erin Weeda; Rachael E Gilbert; Shelby J Kolo; Jason S Haney; Linh Tran Hazard; David J Taber; Robert Neal Axon
Journal:  J Pharm Pract       Date:  2021-12-28

Review 3.  Readmission After ACS: Burden, Epidemiology, and Mitigation.

Authors:  Peter K Boulos; John C Messenger; Stephen W Waldo
Journal:  Curr Cardiol Rep       Date:  2022-04-30       Impact factor: 3.955

4.  Accuracy of Computable Phenotyping Approaches for SARS-CoV-2 Infection and COVID-19 Hospitalizations from the Electronic Health Record.

Authors:  Rohan Khera; Bobak J Mortazavi; Benjamin D Pollock; Wade L Schulz; Veer Sangha; Frederick Warner; H Patrick Young; Joseph S Ross; Nilay D Shah; Elitza S Theel; William G Jenkinson; Camille Knepper; Karen Wang; David Peaper; Richard A Martinello; Cynthia A Brandt; Zhenqiu Lin; Albert I Ko; Harlan M Krumholz
Journal:  medRxiv       Date:  2021-05-13

5.  Evaluation of Risk-Adjusted Home Time After Acute Myocardial Infarction as a Novel Hospital-Level Performance Metric for Medicare Beneficiaries.

Authors:  Ambarish Pandey; Neil Keshvani; Mary S Vaughan-Sarrazin; Yubo Gao; Saket Girotra
Journal:  Circulation       Date:  2020-05-15       Impact factor: 39.918

6.  A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations.

Authors:  Rohan Khera; Bobak J Mortazavi; Veer Sangha; Frederick Warner; H Patrick Young; Joseph S Ross; Nilay D Shah; Elitza S Theel; William G Jenkinson; Camille Knepper; Karen Wang; David Peaper; Richard A Martinello; Cynthia A Brandt; Zhenqiu Lin; Albert I Ko; Harlan M Krumholz; Benjamin D Pollock; Wade L Schulz
Journal:  NPJ Digit Med       Date:  2022-03-08

7.  Readmission and mortality among heart failure patients with history of hypertension in a statewide database.

Authors:  Michail Giakoumis; Davit Sargsyan; John B Kostis; Javier Cabrera; Sanketkumar Dalwadi; William J Kostis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-07       Impact factor: 3.738

8.  Post-discharge acute care and outcomes following readmission reduction initiatives: national retrospective cohort study of Medicare beneficiaries in the United States.

Authors:  Rohan Khera; Yongfei Wang; Susannah M Bernheim; Zhenqiu Lin; Harlan M Krumholz
Journal:  BMJ       Date:  2020-01-15

9.  Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata, 2011 to 2016.

Authors:  Rohan Khera; Nitin Kondamudi; Lin Zhong; Muthiah Vaduganathan; Joshua Parker; Sandeep R Das; Justin L Grodin; Ethan A Halm; Jarett D Berry; Ambarish Pandey
Journal:  JAMA Netw Open       Date:  2020-10-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.